resTORbio Inc. (ACET)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

200 CLARENDON STREET BOSTON, MA 02116

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Data as of 2021-08-02 08:58:38 -0400
Market Cap235.42 Million Shares Outstanding31.814 Million Avg 30-day Volume104.804 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE2.4 Enterprise Value
Total Cash Current Debt Gross Profit
BETA-0.50109 52-week High/Low21.4 / 1.88 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from ACET instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 1 100.0% 0 (0.0%) 0 (0.0%)
Funds Holding: 55 45 22.22% 26 (1.53%) 17 (0.99%) 52.94%
13F shares: 20.394 Million 9.537 Million 113.84% 15.652 Million 7.73 Million 102.49%
% Ownership 64.1704 26.1638 145.26% 49.2497 21.206 132.24%
New Positions: 16 12 33.33% 10 4 150.0%
Increased Positions 21 14 50.0% 10 6 66.67%
Closed Positions 6 2 200.0% 1 1 0.0%
Reduced Positions 9 9 0.0% 4 4 0.0%
Total Calls 0 40 -100.0%
Total Puts
PUT/CALL Ratio 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ACET (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACET BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

20.3 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SCHOR CHEN PRESIDENT & CEO

  • Officer
  • Director
164,677 2021-06-16 14

JAKOBOVITS AYA

  • Director
896,764 2021-06-15 6

ABBOT STEWART SEE REMARKS

  • Officer
5,000 2021-06-11 5

GALIMI FRANCESCO SVP & CHIEF MEDICAL OFFICER

  • Officer
128,424 2021-06-04 5

CHODAKEWITZ JEFFREY

  • Director
18,500 2021-04-30 2

GORDON CARL L

  • Director
18,500 2021-04-30 4

DUBIN STEVE

  • Director
18,500 2021-04-30 3

SANNA BASTIANO

  • Director
19,672 2021-04-30 3

SINCLAIR ANDREW

  • Director
26,672 2021-04-30 5

KLICKSTEIN LLOYD CHIEF INNOVATION OFFICER

  • Officer
0 2021-02-12 4

HARVEY BRIAN NICHOLAS CHIEF FINANCIAL OFFICER

  • Officer
0 2021-02-12 3

KREHLIK CARRIE CHIEF HUMAN RESOURCES OFFICER

  • Officer
0 2021-02-12 4

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ORBIMED CAPITAL GP VI LLC

ORBIMED ADVISORS ISRAEL II LTD

ORBIMED ISRAEL GP II, L.P.

ORBIMED ISRAEL GP LTD.

ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP

  • Director
  • 10% Owner
7,232,856 2021-02-12 2

CHIMOVITS EREZ

  • Director
  • 10% Owner
7,232,856 2021-02-12 3

HEALEY DON CHIEF TECHNOLOGY OFFICER

  • Officer
0 2021-02-12 4

ORBIMED CAPITAL GP V LLC

ORBIMED ADVISORS ISRAEL II LTD

ORBIMED ISRAEL GP II, L.P.

ORBIMED ISRAEL GP LTD.

ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP

  • Director
0 2020-09-15 1

SCHINDEL YAIR CHAIM

  • Director
0 2020-09-15 2

STEINBERG DAVID ADAM

  • Director
0 2020-06-03 0

FONTEYNE PAUL R.

  • Director
0 2020-06-03 0

GRISSINGER MICHAEL

  • Director
0 2020-06-03 0

SILVERSTEIN JONATHAN

  • Director
0 2020-06-03 0

SULLIVAN LYNNE MARIE

  • Director
0 2020-06-03 0

PURETECH HEALTH LLC

  • 10% Owner
2,119,696 2019-12-18 0

MCCABE JOHN J VICE PRESIDENT, FINANCE

  • Officer
12,867 2019-12-06 0

MANNICK JOAN CHIEF MEDICAL OFFICER

  • Officer
2,004,585 2019-12-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SCHOR CHEN - Director - Officer PRESIDENT & CEO see footnote

2021-06-21 16:25:29 -0400 2021-06-16 S 8,982 $10.53 d 89,836 indirect yes -2.6483 7.2034 -23.1992 9.0042 7 -23.1992 31

SCHOR CHEN - Director - Officer PRESIDENT & CEO see footnote

2021-06-21 16:25:29 -0400 2021-06-16 S 7,484 $10.53 d 74,841 indirect yes -2.6483 7.2034 -23.1992 9.0042 7 -23.1992 31

JAKOBOVITS AYA - Director see footnote

2021-06-17 18:08:36 -0400 2021-06-15 S 1,923 $11.16 d 215,883 indirect yes -2.4668 -7.9696 -30.1708 0.0 1 -30.1708 31

JAKOBOVITS AYA - Director see footnote

2021-06-17 18:08:36 -0400 2021-06-15 S 1,924 $11.16 d 215,883 indirect yes -2.4668 -7.9696 -30.1708 0.0 1 -30.1708 31

ABBOT STEWART - Officer SEE REMARKS

2021-06-14 16:28:37 -0400 2021-06-11 A 5,000 a 5,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ADICET BIO INC ACET 2021-08-05 22:15:04 UTC -2.5047 2.5847 150000
ADICET BIO INC ACET 2021-08-05 21:45:03 UTC -2.5047 2.5847 150000
ADICET BIO INC ACET 2021-08-05 21:15:03 UTC -2.5047 2.5847 150000
ADICET BIO INC ACET 2021-08-05 20:45:03 UTC -2.2141 2.2941 150000
ADICET BIO INC ACET 2021-08-05 20:15:04 UTC -2.2141 2.2941 150000
ADICET BIO INC ACET 2021-08-05 19:45:04 UTC -2.2141 2.2941 150000
ADICET BIO INC ACET 2021-08-05 19:15:03 UTC -2.2141 2.2941 150000
ADICET BIO INC ACET 2021-08-05 18:45:03 UTC -2.2141 2.2941 150000
ADICET BIO INC ACET 2021-08-05 18:15:03 UTC -2.2141 2.2941 150000
ADICET BIO INC ACET 2021-08-05 17:45:03 UTC -2.2141 2.2941 150000
ADICET BIO INC ACET 2021-08-05 17:15:03 UTC -2.2141 2.2941 150000
ADICET BIO INC ACET 2021-08-05 16:45:02 UTC -2.2731 2.3531 150000
ADICET BIO INC ACET 2021-08-05 16:15:03 UTC -2.2731 2.3531 150000
ADICET BIO INC ACET 2021-08-05 15:45:03 UTC -2.2731 2.3531 150000
ADICET BIO INC ACET 2021-08-05 15:15:02 UTC -2.2731 2.3531 150000
ADICET BIO INC ACET 2021-08-05 14:45:02 UTC -2.5713 2.6513 150000
ADICET BIO INC ACET 2021-08-05 14:15:04 UTC -2.5713 2.6513 150000
ADICET BIO INC ACET 2021-08-05 13:45:04 UTC -2.5713 2.6513 150000
ADICET BIO INC ACET 2021-08-05 13:15:03 UTC -2.5713 2.6513 150000
ADICET BIO INC ACET 2021-08-05 12:45:03 UTC -2.5713 2.6513 150000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments